NP35925 Cardiovascular & Respiratory Medicines This Framework Agreement is for the supply of Cardiovascular & Respiratory Medicines to health boards across NHS Scotland. The Goods have been split into nineteen (19) categories, each of which is identified as a "Lot". Full details of each Lot is contained in section II.2 of this notice. ... Supply ... The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) NP35925 Cardiovascular & Respiratory Medicines - Opportunity NP35925 Cardiovascular & Respiratory Medicines The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) F02: Contract notice Notice reference: 2024/S 000-033950 Published 21 October 2024, 2:00pm Watch this notice Contents Open all one. Contracting authorityI. Contracting authorityPress escape key to exit two. Object (19 lots)II. Object (19 lots) Scope of the procurement Lot 1. Epoprostenol Powder and Solvent (pH 10.5) for Solution for Infusion Vials Lot 2. Epoprostenol Powder and Solvent (pH 12) for Solution for Infusion Vials Lot 3. Epinephrine (Adrenaline) Pre-Filled Syringes Lot 4. Epinephrine (Adrenaline) Auto Injector Devices Lot 5. Enoxaparin Sodium Injection Lot 6. Urokinase Injections Lot 7. Isosorbide Mononitrate Modified-Release (M/R) Capsules and Tablets Lot 8. Diltiazem Hydrochloride Modified-Release (M/R) Capsules and Tablets Lot 9. Verapamil Hydrochloride Modified-Release (M/R) Capsules and Tablets Lot 10. Nifedipine Modified-Release (M/R) Capsules and Tablets Lot 11. Theophylline Modified-Release (M/R) Capsules and Tablets Lot 12. Branded and Branded Generic Inhalers Lot 13. Iloprost Medicines Lot 14. Dalteparin Injections Lot 15. Tinzaparin Sodium Injections Lot 16. Icatibant Solution for Injection Lot 17. Treprostinil Injection Lot 18. Direct Acting Oral Anticoagulants (DOACs) Lot 19. All Other Cardiovascular & Respiratory Medicines three. Legal, economic, financial and technical informationIII. Legal, economic, financial and technical information four. ProcedureIV. Procedure six. Complementary informationVI. Complementary information Download PDF version Share this notice Twitter LinkedIn Email Copy link Print this notice Report concerns about this procurement Section one: Contracting authoritySection I: Contracting authority one.1) Name and addressesI.1) Name and addresses The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) 1 South Gyle Crescent Edinburgh EH12 9EB Email marta.siwek@nhs.scot Telephone +44 07483141961 Country United Kingdom NUTS code UKM - Scotland Internet address(es) Main address http://www.nss.nhs.scot/browse/procurement-and-logistics Buyer's address https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883 one.2) Information about joint procurementI.2) Information about joint procurement The contract is awarded by a central purchasing body one.3) CommunicationI.3) Communication The procurement documents are available for unrestricted and full direct access, free of charge, at https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html Additional information can be obtained from the above-mentioned address Tenders or requests to participate must be submitted electronically via https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html one.4) Type of the contracting authorityI.4) Type of the contracting authority Body governed by public law one.5) Main activityI.5) Main activity Health Section two: ObjectSection II: Object two.1) Scope of the procurementII.1) Scope of the procurement two.1.1) TitleII.1.1) Title NP35925 Cardiovascular & Respiratory Medicines two.1.2) Main CPV codeII.1.2) Main CPV code 33600000 - Pharmaceutical products two.1.3) Type of contractII.1.3) Type of contract Supplies two.1.4) Short descriptionII.1.4) Short description This Framework Agreement is for the supply of Cardiovascular & Respiratory Medicines to health boards across NHS Scotland. The Goods have been split into nineteen (19) categories, each of which is identified as a "Lot". Full details of each Lot is contained in section II.2 of this notice. two.1.5) Estimated total valueII.1.5) Estimated total value Value excluding VAT: £95,148,458 two.1.6) Information about lotsII.1.6) Information about lots This contract is divided into lots: Yes Tenders may be submitted for all lots two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Epoprostenol Powder and Solvent (pH 10.5) for Solution for Infusion Vials Lot No 1 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Epoprostenol 500mcg and 1.5mg powder and solvent (pH10.5) for solution for infusion vials to NHS Scotland. The Authority intends awarding a multi-supplier unranked framework agreement for the Lot and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £100,000 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Epoprostenol Powder and Solvent (pH 12) for Solution for Infusion Vials Lot No 2 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Epoprostenol 500mcg and 1.5mg powder and solvent (pH12) for solution for infusion vials to NHS Scotland. The Authority intends awarding a multi-supplier unranked framework agreement for the Lot and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £4,541,953 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Epinephrine (Adrenaline) Pre-Filled Syringes Lot No 3 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Epinephrine (Adrenaline) Pre-filled syringes to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £1,555,316 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Epinephrine (Adrenaline) Auto Injector Devices Lot No 4 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Epinephrine (Adrenaline) Auto Injector Devices to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £813,471 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Enoxaparin Sodium Injection Lot No 5 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Enoxaparin Sodium Injection to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £15,288,661 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Urokinase Injections Lot No 6 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Urokinase Injections to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £472,523 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Isosorbide Mononitrate Modified-Release (M/R) Capsules and Tablets Lot No 7 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Isosorbide Mononitrate Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £191,878 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Diltiazem Hydrochloride Modified-Release (M/R) Capsules and Tablets Lot No 8 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Diltiazem Hydrochloride Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £119,355 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Verapamil Hydrochloride Modified-Release (M/R) Capsules and Tablets Lot No 9 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Verapamil Hydrochloride Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £62,465 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Nifedipine Modified-Release (M/R) Capsules and Tablets Lot No 10 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Nifedipine Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £136,569 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Theophylline Modified-Release (M/R) Capsules and Tablets Lot No 11 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Theophylline Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £32,341 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Branded and Branded Generic Inhalers Lot No 12 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Branded and Branded Generic Inhalers to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £4,897,823 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Iloprost Medicines Lot No 13 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Iloprost Solutions for Infusion and Nebuliser solutions to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £1,572,128 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Dalteparin Injections Lot No 14 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Dalteparin Injection to NHS Scotland in a range of presentations. The Authority intends awarding a multi supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded per line. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £17,380,231 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Tinzaparin Sodium Injections Lot No 15 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Tinzaparin Sodium Injection to NHS Scotland in a range of presentations. The Authority intends awarding a multi supplier unranked framework agreement on a lot basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £836,630 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Icatibant Solution for Injection Lot No 16 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Icatibant Solution for Injection to NHS Scotland. The Authority intends awarding a multi supplier ranked Framework Agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded per line. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £381,184 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Treprostinil Injection Lot No 17 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Treprostinil Injection to NHS Scotland in a range of presentations. The Authority intends awarding an unranked multi supplier framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £283,678 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title Direct Acting Oral Anticoagulants (DOACs) Lot No 18 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of Direct Acting Oral Anticoagulants (DOACs) to NHS Scotland in a range of presentations. The Authority intends awarding a multi supplier ranked Framework Agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded per line. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £12,053,015 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No two.2) DescriptionII.2) Description two.2.1) TitleII.2.1) Title All Other Cardiovascular & Respiratory Medicines Lot No 19 two.2.2) Additional CPV code(s)II.2.2) Additional CPV code(s) 33600000 - Pharmaceutical products two.2.3) Place of performanceII.2.3) Place of performance NUTS codes UKM - Scotland Main site or place of performance All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014. two.2.4) Description of the procurementII.2.4) Description of the procurement Supply of All Other Cardiovascular & Respiratory Medicines to NHS Scotland in a range of presentations. Each product line will be treated as an individual Lot. The Authority intends awarding each product line to a single Framework Participant. Full details can be found within the ITT. two.2.5) Award criteriaII.2.5) Award criteria Quality criterion - Name: Logistics / Weighting: 5 Price - Weighting: 95 two.2.6) Estimated valueII.2.6) Estimated value Value excluding VAT: £34,429,229 two.2.7) Duration of the contract, framework agreement or dynamic purchasing systemII.2.7) Duration of the contract, framework agreement or dynamic purchasing system Duration in months 36 This contract is subject to renewal Yes Description of renewals This framework includes the option(s) to extend for period(s) up to a total period of twenty-four (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire. two.2.10) Information about variantsII.2.10) Information about variants Variants will be accepted: No two.2.11) Information about optionsII.2.11) Information about options Options: No two.2.13) Information about European Union FundsII.2.13) Information about European Union Funds The procurement is related to a project and/or programme financed by European Union funds: No Section three. Legal, economic, financial and technical informationSection III. Legal, economic, financial and technical information three.1) Conditions for participationIII.1) Conditions for participation three.1.1) Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registersIII.1.1) Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers List and brief description of conditions Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015. three.1.3) Technical and professional abilityIII.1.3) Technical and professional ability List and brief description of selection criteria (a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL,PLGB or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender. (b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent at the date of submission of the tender. (c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design. (d) Potential Framework Participants are required to provide evidence that their organisation has taken steps to build their awareness of the climate change emergency and how they will respond. Minimum level(s) of standards possibly required (a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender, should be included in the Qualification Envelope of the ITT under the Technical and Professional ability: Quality Control. (b) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent at the date of submission of the tender should be included in the Qualification Envelope of the ITT under the Quality Assurance Schemes. (c) Confirmation that samples for tendered Goods will be supplied upon request to ensure compliance with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design. Confirmation of sample provision should be provided in the Qualification Envelope of the ITT under Technical and Professional ability: Products (d) A completed copy of the Bidder Climate Change Plan Template, including planned projects and actions to reduce the bidder’s carbon emissions should be provided in the Qualification Envelope of the ITT under Environmental Management Criteria. This does not need to contain calculated carbon emissions. Section four. ProcedureSection IV. Procedure four.1) DescriptionIV.1) Description four.1.1) Type of procedureIV.1.1) Type of procedure Open procedure four.1.3) Information about a framework agreement or a dynamic purchasing systemIV.1.3) Information about a framework agreement or a dynamic purchasing system The procurement involves the establishment of a framework agreement Framework agreement with several operators four.1.8) Information about the Government Procurement Agreement (GPA)IV.1.8) Information about the Government Procurement Agreement (GPA) The procurement is covered by the Government Procurement Agreement: Yes four.2) Administrative informationIV.2) Administrative information four.2.2) Time limit for receipt of tenders or requests to participateIV.2.2) Time limit for receipt of tenders or requests to participate Date 20 November 2024 Local time 12:00pm four.2.4) Languages in which tenders or requests to participate may be submittedIV.2.4) Languages in which tenders or requests to participate may be submitted English four.2.6) Minimum time frame during which the tenderer must maintain the tenderIV.2.6) Minimum time frame during which the tenderer must maintain the tender Duration in months: 3 (from the date stated for receipt of tender) four.2.7) Conditions for opening of tendersIV.2.7) Conditions for opening of tenders Date 20 November 2024 Local time 12:00pm Section six. Complementary informationSection VI. Complementary information six.1) Information about recurrenceVI.1) Information about recurrence This is a recurrent procurement: No six.2) Information about electronic workflowsVI.2) Information about electronic workflows Electronic ordering will be used Electronic invoicing will be accepted Electronic payment will be used six.3) Additional informationVI.3) Additional information The estimated value(s) referred to in Section II.1.5 and within all Lots cover(s) the thirty six (36) month contract duration and the twenty four (24) month extension period of the framework agreement. The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 27594. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343 A sub-contract clause has been included in this contract. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2363 Community benefits are included in this requirement. For more information see: https://www.gov.scot/policies/public-sector-procurement/community-benefits-in-procurement/ A summary of the expected community benefits has been provided as follows: It is a mandatory requirement that potential framework participants/contractors agree to support the concept, provision, and ongoing development of community benefits provision in relation to this framework/contract. Potential framework participants/contractors are required to agree to this mandatory requirement. They are also requested to provide a summary of the community benefits that have recently been delivered within Scotland, if at all, and what impact and outcomes these have achieved. Potential framework participants/contractors are required to summarise any proposed community benefits that will be developed and delivered as part of this framework/contract if successful or, alternatively, potential framework participants/contractors confirm that they will engage with the NHS Scotland’s Community Benefits Gateway (CBG). This gateway, developed through requests from suppliers seeking opportunities to support the delivery of community benefits within the contracting region, provides information on community benefit opportunities. The CBG is a free and easy to use online service that connects NHS Scotland suppliers with third sector community organisations within Scotland and will be used for tracking and reporting and is an approved compliant route to the realisation of community benefits. For further information please visit NHSS Community Benefit Gateway (https://www.nss.nhs.scot/procurement-and-logistics/sustainability/access-our-community-benefit-gateway/). (SC Ref:777704) six.4) Procedures for reviewVI.4) Procedures for review six.4.1) Review bodyVI.4.1) Review body Sheriff Court House 27 Chambers Street Edinburgh EH1 1LB Email edinburgh@scotcourts.gov.uk Country United Kingdom Internet address https://www.scotcourts.gov.uk/the-courts/court-locations/edinburgh-sheriff-court-and-justice-of-the-peace-court six.4.3) Review procedureVI.4.3) Review procedure Precise information on deadline(s) for review procedures The Authority will notify economic operators who submitted a tender or (where no deselection notification has previously been made) applied to be selected to tender, of its decision to award the framework agreement which notification will contain among other information, a summary of the reasons why the economic operators was unsuccessful. The notification will incorporate a ‘standstill period’ of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority dispatches the notice(s) and the date on which the Authority proposes to conclude the relevant framework agreement. The bringing of court proceedings against the Authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued, or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer(s). The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages. Back to top 1729552488 Support links About us Contact us Accessibility statement Terms and conditions Privacy notice Cookies Data and API All content is available under the Open Government Licence v3.0 except where otherwise stated. Notices are based on TED XML schema. © European Union, https://ted.europa.eu, 1998–2020 © Crown copyright Review services If you have any concerns about procurement practices, including late payment, you can contact a review service. The role of the services is to: provide a clear, structured and direct route for suppliers to raise concerns about public procurement practice offer feedback to enquirers on their concerns Find out more: England - Public Procurement Review Service Northern Ireland - CPD Supplier Charter Scotland - Single Point of Enquiry Wales - Supplier Feedback Service Close Saved to watched notices list This notice has been added to your watched notices list. Close Sign in to watch this notice To watch this notice, sign in to your account or register. You will need to find this notice again after signing in to watch it. Watching a notice means: It will be in your list of watched notices, so you can easily find it again You can choose to receive emails when it is updated or before it closes Close Confirm YesNo Session timeout Your session will time out soon You will be signed out of your account if you do not respond in 5 minutes. We do this to keep your information secure. 5 minutes remaining until you will be signed out. Continue session Sign out warning you will not be able to undo this action NP35925 Cardiovascular & Respiratory MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)  This Framework Agreement is for the supply of Cardiovascular & Respiratory Medicines to health boards across NHS Scotland. The Goods have been split into nineteen (19) categories, each of which is identified as a "Lot". Full details of each Lot is contained in section II.2 of this notice. ... Supply ...  Notice typeF02: Contract noticeClosing20 November 2024, 12:00pmContract locationUKM - ScotlandTotal value £95,148,458 Lot values £100,000; £4,541,953; £1,555,316; £813,471; £15,288,661; £472,523; £191,878; £119,355; £62,465; £136,569; £32,341; £4,897,823; £1,572,128; £17,380,231; £836,630; £381,184; and 3 more Publication date21 October 2024, 2:00pm